Skip to main content
Peer Review

Peer Reviewed

Clinical Images

Self-Expanding Transcatheter Aortic Valve Replacement for Pure Aortic Regurgitation With Extremely Horizontal Aorta: A Case Series

Hanyi Dai, MD*; Dao Zhou, MD*; Abuduwufuer Yidilisi, MD;  Xianbao Liu, MD, PhD; Jian’an Wang, MD, PhD

March 2022
1557-2501
J INVASIVE CARDIOL 2022;34(3):E257-E258. doi: 10.25270/jic/21.00382

Citation

J INVASIVE CARDIOL 2022;34(3):E257-E258.

Key words: horizontal aorta, pure aortic regurgitation, transcatheter aortic valve replacement

Case Presentation

Transcatheter aortic valve replacement (TAVR) is not the preferred therapy for pure aortic regurgitation (AR). Extremely horizontal aorta (aorta root angle ≥70°) is regarded as an “off-label” use in self-expanding TAVR. This case series enrolled 7 consecutive pure AR patients who had extremely horizontal aorta and underwent self-expanding TAVR from the TORCH registry (NCT02803294). The mean age was 74.1 ± 8.3 years and the Society of Thoracic Surgeons (STS) score was 3.8 ± 1.5%. All patients lacked calcification at the aortic root. Transapical TAVR with a J-valve (Jiecheng) was performed in 5 patients and transfemoral TAVR with a Venus-A valve (Medtech) was performed in 2 patients (Figure 1 Part 1 and Figure 1 Part 2).

Case 1 received permanent pacemaker implantation and suffered a non-disabling stroke, while case 4 and case 5 suffered major bleeding during 30-day follow-up. Detailed aortic angulation measurement and fluoroscopy during the procedure are shown in Figure 1 Part 1 and Figure 1 Part 2. Nevertheless, procedural success was achieved in all patients according to Valve Academic Research Consortium-2 definitions and no patients were at New York Heart Association class III/IV at 30 days. To the best of our knowledge, this is the first study to report successful self-expanding TAVR for pure AR with extremely horizontal aorta, revealing the feasibility of both transapical and transfemoral TAVR in this challenging population.

Dai Figure 1A-1D

Dai Figure 1E-1H